Page 42 - Haematologica-April 2018

F. Pasquier et al.
ed with familial erythrocytosis cause
hypersensitivity to erythropoietin in the heterozygous state. Blood. 1999;94(7): 2530-2532.
10. Kralovics R, Prchal JT. Genetic heterogene- ity of primary familial and congenital poly- cythemia. Am J Hematol. 2001;68(2):115- 121.
11. Arcasoy MO, Karayal AF, Segal HM, Sinning JG, Forget BG. A novel mutation in the erythropoietin receptor gene is associ- ated with familial erythrocytosis. Blood. 2002;99(8):3066-3069.
12. Rives S, Pahl HL, Florensa L, et al. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica. 2007;92(5):674-677.
13. Al-Sheikh M, Mazurier E, Gardie B, et al. A study of 36 unrelated cases with pure ery- throcytosis revealed three new mutations in the erythropoietin receptor gene. Haematologica. 2008;93(7):1072-1075.
14. Perrotta S, Cucciolla V, Ferraro M, et al. EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors. PLoS One. 2010;5(8):e12015.
15. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes poly- cythaemia vera. Nature. 2005;434(7037): 1144-1148.
16. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459-468.
17. D'Andrea AD, Fasman GD, Lodish HF. Erythropoietin receptor and interleukin-2 receptor beta chain: a new receptor family. Cell. 1989;58(6):1023-1024.
18. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell sur- face expression of erythropoietin receptor. Mol Cell. 2001;8(6):1327-1338.
19. Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoi- etin receptor and is tyrosine phosphorylat- ed and activated following stimulation with erythropoietin. Cell. 1993;74(2):227- 236.
20. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, Lodish HF. Ineffective ery- thropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood. 2001;98(12):3261-3273.
21. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progeni- tor proliferation. Blood. 2003;101(9):3436- 3443.
22. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin recep- tor. Cell. 1995;83(1):59-67.
23. Petersen KB, Hokland P, Petersen GB, Nyvold CG. Erythropoietin receptor defect: a cause of primary polycythaemia. Br J
Haematol. 2004;125(4):537-538.
24. O'Rourke K, Fairbairn DJ, Jackson KA, Morris KL, Tey SK, Kennedy GA. A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia. Int J Hematol.
2011;93(4):542-544.
25. Bento C, Almeida H, Maia TM, et al.
Molecular study of congenital erythrocyto- sis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (where is/are the missing gene(s)?). Eur J Haematol. 2013;91(4):361- 368.
26. Bento C, Percy MJ, Gardie B, et al. Genetic basis of congenital erythrocytosis: muta- tion update and online databases. Hum Mutat. 2014;35(1):15-26.
27. Gross M, Ben-Califa N, McMullin MF, et al. Polycythaemia-inducing mutations in the erythropoietin receptor (EPOR): mecha- nism and function as elucidated by epider- mal growth factor receptor-EPOR chimeras. Br J Haematol. 2014;165(4):519- 528.
28. Chauveau A, Luque Paz D, Lecucq L, et al. A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis. Br J Haematol. 2016;172(3):475-477.
29. Iacobucci I, Li Y, Roberts KG, et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell. 2016;29(2):186-200.
30. Sulahian R, Cleaver O, Huang LJ. Ligand- induced EpoR internalization is mediated by JAK2 and p85 and is impaired by muta- tions responsible for primary familial and congenital polycythemia. Blood. 2009;113(21):5287-5297.
31. Bulut GB, Sulahian R, Yao H, Huang LJ. Cbl ubiquitination of p85 is essential for Epo- induced EpoR endocytosis. Blood. 2013;122(24):3964-3972.
32. Le Couedic JP, Mitjavila MT, Villeval JL, et al. Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignancies. Blood. 1996;87(4):1502-1511.
33. Remy I, Michnick SW. A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods. 2006;3(12):977-979.
34. Verdier F, Walrafen P, Hubert N, et al. Proteasomes regulate the duration of ery- thropoietin receptor activation by control- ling down-regulation of cell surface recep- tors. J Biol Chem. 2000;275(24):18375- 18381.
35. Walrafen P, Verdier F, Kadri Z, Chretien S, Lacombe C, Mayeux P. Both proteasomes and lysosomes degrade the activated ery- thropoietin receptor. Blood. 2005;105(2): 600-608.
36. Meyer L, Deau B, Forejtnikova H, et al. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood. 2007;109(12):5215-5222.
37. Letourneur F, Klausner RD. A novel di- leucine motif and a tyrosine-based motif independently mediate lysosomal targeting
and endocytosis of CD3 chains. Cell.
1992;69(7):1143-1157.
38. Jiao H, Berrada K, Yang W, Tabrizi M,
Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyro- sine phosphatase SHP-1. Mol Cell Biol. 1996;16(12):6985-6992.
39. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS-3 sup- presses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000;275(38):29338-29347.
40. Arcasoy MO, Harris KW, Forget BG. A human erythropoietin receptor gene mutant causing familial erythrocytosis is associated with deregulation of the rates of Jak2 and Stat5 inactivation. Exp Hematol. 1999;27(1):63-74.
41. D'Andrea AD, Yoshimura A, Youssoufian H, Zon LI, Koo JW, Lodish HF. The cyto- plasmic region of the erythropoietin recep- tor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol. 1991;11(4):1980-1987.
42. Kim AR, Ulirsch JC, Wilmes S, et al. Functional selectivity in cytokine signaling revealed through a pathogenic EPO muta- tion. Cell. 2017;168(6):1053-1064 e1015.
43. Moraga I, Wernig G, Wilmes S, et al. Tuning cytokine receptor signaling by re- orienting dimer geometry with surrogate ligands. Cell. 2015;160(6):1196-1208.
44. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283 (5404):987-990.
45. Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF. Ligand- independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci USA. 2001;98(8):4379-4384.
46. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395(6701):511-516.
47. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydropho- bic motif. Mol Cell. 2001;7(2):377-385.
48. Lu X, Gross AW, Lodish HF. Active confor- mation of the erythropoietin receptor: ran- dom and cysteine-scanning mutagenesis of the extracellular juxtamembrane and trans- membrane domains. J Biol Chem. 2006;281 (11):7002-7011.
49. Li Q, Wong YL, Huang Q, Kang C. Structural insight into the transmembrane domain and the juxtamembrane region of the erythropoietin receptor in micelles. Biophys J. 2014;107(10):2325-2336.
50. Seubert N, Royer Y, Staerk J, et al. Active and inactive orientations of the transmem- brane and cytosolic domains of the ery- thropoietin receptor dimer. Mol Cell. 2003;12(5):1239-1250.
586
haematologica | 2018; 103(4)